{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T05:22:36Z","timestamp":1774156956376,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1111\/igc.0b013e3181e273a8","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T14:24:44Z","timestamp":1291386284000},"page":"787-793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer"],"prefix":"10.1016","volume":"20","author":[{"given":"Stephen A.","family":"Welch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hal W.","family":"Hirte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Elit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russel J.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina","family":"MacAlpine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/IGC.0b013e3181e273a8_bb0005","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1008240421028","article-title":"Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients","volume":"8","author":"Eisenhauer","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0010","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jnci\/90.6.447","article-title":"Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice","volume":"90","author":"Yoneda","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0020","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/cncr.20449","article-title":"Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma","volume":"101","author":"Nishida","year":"2004","journal-title":"Cancer"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0025","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0035","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0040","doi-asserted-by":"crossref","first-page":"LBA1","DOI":"10.1200\/jco.2007.25.18_suppl.lba1","article-title":"Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)","volume":"25","author":"Llovet","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0045","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/1078-0432.CCR-05-1571","article-title":"Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer","volume":"12","author":"Siu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0055","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1136\/ijgc-00009577-200509000-00001","article-title":"CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use","volume":"15","author":"Duffy","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0065","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00001813-199512006-00010","article-title":"Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients","volume":"6","author":"Lund","year":"1995","journal-title":"Anticancer Drugs"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","article-title":"Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel","volume":"63","author":"Shapiro","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0075","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1023\/A:1008469212268","article-title":"A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer","volume":"9","author":"Friedlander","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0080","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1023\/A:1008364327684","article-title":"Phase II study of gemcitabine in ovarian cancer","volume":"10","author":"von Minckwitz","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0085","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0090-8258(03)00011-8","article-title":"Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer","volume":"88","author":"D\u2019Agostino","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0090","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0090-8258(03)00399-8","article-title":"Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer","volume":"90","author":"Markman","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0095","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0100","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0105","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma","volume":"68","author":"Bast","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0110","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1200\/JCO.2003.08.148","article-title":"The myth of measurable disease in ovarian cancer","volume":"21","author":"Markman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0115","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1200\/JCO.2000.18.8.1733","article-title":"Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials","volume":"18","author":"Rustin","year":"2000","journal-title":"J Clin Oncol"},{"issue":"abstr 5537","key":"10.1111\/IGC.0b013e3181e273a8_bb0120","article-title":"Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study","volume":"26","author":"Matei","year":"2008","journal-title":"J Clin Oncol"},{"issue":"abstr 5521","key":"10.1111\/IGC.0b013e3181e273a8_bb0125","article-title":"A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial","volume":"26","author":"Hirte","year":"2008","journal-title":"J Clin Oncol"},{"issue":"abstr 5522","key":"10.1111\/IGC.0b013e3181e273a8_bb0130","article-title":"A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma-NCIC CTG IND 185","volume":"26","author":"Biagi","year":"2008","journal-title":"J Clin Oncol"},{"issue":"abstr 5501","key":"10.1111\/IGC.0b013e3181e273a8_bb0135","article-title":"Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer","volume":"26","author":"Matulonis","year":"2008","journal-title":"J Clin Oncol"},{"issue":"abstr 5508","key":"10.1111\/IGC.0b013e3181e273a8_bb0140","article-title":"VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study","volume":"25","author":"Tew","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0145","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0150","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0155","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago and Princess Margaret Hospital Consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0160","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ygyno.2008.02.009","article-title":"Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia","volume":"110","author":"Nimeiri","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0165","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0170","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/IGC.0b013e3181e273a8_bb0175","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago and Princess Margaret Hospital Consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"issue":"abstract 5537","key":"10.1111\/IGC.0b013e3181e273a8_bb0180","article-title":"Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study","volume":"26","author":"Matei","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2FIGC.0b013e3181e273a8","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24036648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24036648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1111\/IGC.0b013e3181e273a8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:18:04Z","timestamp":1753233484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24036648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S1048891X24036648"],"URL":"https:\/\/doi.org\/10.1111\/igc.0b013e3181e273a8","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/IGC.0b013e3181e273a8","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 by IGCS and ESGO","name":"copyright","label":"Copyright"}]}}